What is Leerink Partnrs’ Estimate for MRSN Q1 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSNFree Report) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a note issued to investors on Monday, March 3rd. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($0.17) per share for the quarter. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.15) EPS and Q4 2025 earnings at ($0.14) EPS.

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $16.36 million during the quarter, compared to analyst estimates of $7.71 million.

Several other analysts also recently weighed in on the company. William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They set an “outperform” rating on the stock. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Mersana Therapeutics in a research note on Monday. Finally, Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.25.

Read Our Latest Stock Analysis on MRSN

Mersana Therapeutics Stock Up 5.9 %

Shares of MRSN stock opened at $0.51 on Tuesday. Mersana Therapeutics has a 1-year low of $0.46 and a 1-year high of $6.28. The stock’s fifty day moving average price is $0.82 and its 200 day moving average price is $1.56. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The company has a market cap of $62.79 million, a price-to-earnings ratio of -0.83 and a beta of 1.39.

Institutional Trading of Mersana Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Novo Holdings A S purchased a new stake in shares of Mersana Therapeutics in the fourth quarter worth about $6,078,000. Rock Springs Capital Management LP boosted its stake in shares of Mersana Therapeutics by 12.6% in the fourth quarter. Rock Springs Capital Management LP now owns 3,431,684 shares of the company’s stock worth $4,907,000 after buying an additional 384,902 shares during the last quarter. State Street Corp boosted its stake in shares of Mersana Therapeutics by 1.6% in the third quarter. State Street Corp now owns 2,725,394 shares of the company’s stock worth $5,151,000 after buying an additional 43,339 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Mersana Therapeutics in the fourth quarter worth about $3,768,000. Finally, Geode Capital Management LLC boosted its stake in shares of Mersana Therapeutics by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,442,250 shares of the company’s stock worth $3,493,000 after buying an additional 29,035 shares during the last quarter. Hedge funds and other institutional investors own 93.92% of the company’s stock.

About Mersana Therapeutics

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

Featured Stories

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.